Objective: To investigate the relationships between plasma leptin and adiponectin levels and recurrent cardiovascular events (cardiovascular death, nonfatal myocardial infarction and stroke) in men with earlier acute coronary syndromes. Design, subjects and measurements: A nested case-control study examined circulating leptin and adiponectin levels in plasma obtained 4-6 years after entry into the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial. Plasma was assayed from 184 men who suffered recurrent events within 4.4 years after blood collection and 184 matched controls who remained free of further events. The association between cardiovascular events and the explanatory variables was examined by conditional logistic regression analysis. Results: Relative risk (RR) increased across increasing leptin quartiles; the highest quartile compared with the lowest quartile was related to the highest risk (P for trend ¼ 0.002); the increased risk remained after adjustment for risk factors (P ¼ 0.018) or for obesity (P ¼ 0.038), but in the final model (adjusted for randomized treatment, other drugs, LIPID risk score, age and body mass index), the risk was attenuated (RR ¼ 1.61, 95% CI: 0.72-3.57, P for trend ¼ 0.34). Adiponectin did not predict cardiovascular events. Subjects randomly allocated to pravastatin had 6% lower leptin levels (P ¼ 0.04) than those allocated to placebo. Conclusion: Plasma leptin was a significant and independent predictor of recurrent cardiovascular events (cardiovascular death, nonfatal myocardial infarction and stroke) in men with earlier acute coronary syndromes.
Introduction
The discovery of the adipocyte-derived hormone, leptin, by Friedman et al. opened a novel area of research concerning weight control and regulation of hunger and fat mass. 1 The physiological role of leptin is complex, 1,2 and it has recently been suggested that leptin could be an important mediator of the relationship among obesity, increasing overweight and cardiovascular disease. 3 Leptin might operate through effects on blood pressure (BP), 4 platelet aggregation, 5 lipid metabolism 6 and vascular function. 7 High leptin levels predict the development of first-ever myocardial infarction and coronary events in men, 8, 9 but so far there are few data on leptin's effects on recurrent events in patients with existing stable coronary heart disease (CHD). Adiponectin is another potential mediator of increased cardiovascular risk in those who are overweight or obese. Low adiponectin levels are associated not only with obesity 10 but also insulin resistance, and predict the development of type 2 diabetes. 11 Adiponectin also modulates the inflammatory response of endothelial cells 12 and influences the neointima formation and the proliferation of vascular smooth cells in experimental models. High levels may protect men against future myocardial infarction, 13 but a study including men and women did not show any association. 14 To address the twin issues of the possible prognostic value of leptin and adiponectin concentrations on future cardiovascular events and the potential interaction with HMG-CoA reductase inhibitors, we determined circulating levels in a sample of patients with preexisting CHD enrolled in the Long-Term Intervention with Pravastatin in Ischaemic Disease study (LIPID) . 15 Potential confounding effects of conventional risk factors and of other biomarkers, such as C-reactive protein (CRP) and N-terminal-pro brain natriuretic peptide (NT-proBNP), were also examined.
Methods

Study population
The LIPID study 15 comprised 9014 patients aged 31-75 years who had suffered a myocardial infarction (MI) or hospital admission for unstable angina (UA) 3-36 months before registration and had plasma total cholesterol of 4.0-7.0 mmol l
À1
and fasting triglycerides o5.0 mmol l
. Patients with heart failure (New York Heart Association classes 3 and 4 or Ejection Fraction o25%) were not eligible for the trial. Patients were screened in 87 centres in Australia and New Zealand between 1990 and 1992. After an 8-week placebo run-in phase, patients were randomly allocated to receive pravastatin at a dose of 40 mg daily or matching placebo. Plasma samples were taken at periodic intervals during follow-up. After closure of the placebo-controlled trial, all patients still alive were seen in clinic visits (wherever possible) and offered open-label pravastatin 40 mg daily. These patients were followed up for an average of a further 2 years. All deaths, myocardial infarctions and strokes were reviewed by outcome assessment committees whose members were blinded to the patient's original treatment assignment. Further follow-up for up to 3 years through death registers has been completed. The LIPID study complies with the Declaration of Helsinki Principles and was approved by the ethics committee at each participating centre. All patients gave written informed consent.
We thus certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers/animals were followed during this research.
Patients were selected randomly from all cases for this substudy. A case was defined as a patient who had had a cardiovascular event at some point between the collection date of the sample for assay (at 4, 5 or 6 years from randomization) and the date of the patient's final visit, whether it was in the placebo-controlled or the open-label phase of the LIPID study ( Figure 1) . A cardiovascular event was defined as cardiovascular death, nonfatal myocardial infarction or ischaemic stroke. The time of the event refers to the earliest event during this period (if more than one occurred) and was calculated from the date of the blood collection. Blood samples from 250 cases and 250 controls were selected in a nested case-control study design. For each case, a matched control was selected at random from among all remaining eligible patients who had not had a cardiovascular event during the same follow-up time from blood collection as the case.
Biomedical factors and biochemical analyses
Lipid level and clinical measurements were performed at randomization. Weight was measured without shoes in light indoor clothing and recorded to the nearest 0.2 kg and height was measured to the nearest centimetre, without shoes. Body mass index (BMI) was calculated as total body weight in kg/(height in metres) squared (kg/m 2 ). Clinical cutoffs for BMI (o25, 25-30, and 30 þ kg/m 2 ) identified normal-weight, overweight and obese subjects, respectively. After 5 min of rest, BP was recorded and hypertension was defined as systolic BPX160 mm Hg and/or diastolic BPX95 mm Hg, and/or a self-reported history of hypertension. The majority (88%) of those with the history of hypertension were on antihypertensive treatment. The presence or absence of diabetes was based on self-report, baseline glucose levels and use of anti-diabetic medications. Patients were grouped as non-smokers, ex-smokers or current smokers on the basis of self-report. On the basis of a risk model developed from the main double-blind phase of the LIPID study, 16 each patient was assigned a risk score, which was used for adjustments in this substudy. The LIPID risk score incorporates total and high-density lipoproteins (HDL) cholesterol, age, sex, smoking status, nature of prior acute coronary syndrome, revascularization and history of stroke, diabetes and hypertension.
To measure leptin and total adiponectin levels, blood was drawn after a 12-h fast into EDTA tubes and was analyzed with double-antibody radioimmunoassays (Linco Res., St Louis, MO, USA). The total coefficient of variation for leptin was 4.7% at both low (2-4 ng ml
À1
) and high (10-15 ng ml À1 ) levels, and for adiponectin was 15.2% at low (2-4 mg ml À1 ) and 8.8% at high (26-54 mg ml À1 ) levels. Plasma NT-proBNP was measured using an electrochemiluminescence sandwich immunoassay (ECLIA, Roche Diagnostics, Mannheim, Germany) on an Elecsys System 2010. Intraassay and interassay precision for the luminescence-sandwich immunoassay were 0.8-3% and 2.2-5.8%, respectively. The linear range of detection of this assay is 5-35 000 pg ml
; crossreactivity with BNP and atrial natriuretic peptide (ANP) was less than 0.001%. CRP was determined by a highly sensitive, latex particle-enhanced immunoassay (detection range of 0-20 mg l
, Roche Diagnostics). Serum lipid levels obtained from fasting patients were measured at the LIPID study's central laboratory, soon after collection with commercially available assays. Leptin and cardiovascular risk S Söderberg et al test. The effect of randomly allocated treatment, casecontrol status and their interaction on log-transformed leptin and adiponectin data was tested by analysis of variance. The Spearman rank correlation and the Wilcoxon signed-rank test were used to assess the relationship between biomarker variables and baseline variables in the control group only. Conditional logistic regression analysis for matched case-control studies was performed to investigate the association between the outcome and the explanatory variables. In these analyses, leptin and adiponectin were treated in quartiles derived from the combined distribution of levels in the cases and controls. Factors affecting leptin levels (BMI and age), cardiovascular risk factors (LIPID score), treatment allocation (pravastatin or not) and other drugs were chosen for the multivariable models. The relative risk (RR) associated with hormone levels was estimated from the linear trend over the medians of each quartile. To test for interactions among leptin, adiponectin, total-to-HDL cholesterol ratio, CRP and NT-proBNP, each of these variables was dichotomized into categories above and below its median. Conditional logistic regressions were used to test the effect of pairs of dichotomized variables and their interaction on the outcome. The RRs and 95% confidence intervals (CIs) are reported. Differences with Po0.05 were considered to be significant. All analyses were carried out with SAS software (version 8.02, SAS Institute).
Results
The initial matching process did not consider sex, and the resulting pairs were 184 male pairs, 61 mixed pairs and 5 female pairs. Because plasma leptin concentrations are higher in women than in men and because there were too few female pairs for a meaningful analysis, only data from the 184 pairs of male subjects were analyzed. The events of these 184 men included 56 coronary deaths, 7 cardiovascular noncoronary deaths, 85 nonfatal myocardial infarctions and 36 nonhaemorrhagic strokes. Overall, the men who had new cardiovascular events were older, heavier, had higher BP and were more likely to have diabetes and a history of smoking (Table 1) . They were also more likely to have had peripheral arterial disease, a myocardial infarction rather than unstable angina as their qualifying diagnosis and to have had multiple myocardial infarctions before their randomization. Accordingly, they were more often treated with diuretics, Ca 2 þ blockers and with oral hypoglycaemic drugs. Total and HDL cholesterol levels were similar at randomization, but triglyceride levels were higher in cases than in controls. Circulating levels of leptin and NT-proBNP (taken after 4, 5 or 6 years) were higher in cases, although not significantly for leptin, whereas levels of adiponectin and CRP did not differ. Patients randomly allocated pravastatin had approximately 6% lower leptin levels than those randomly allocated to placebo (P ¼ 0.04). No pravastatinrelated effects on adiponectin levels were observed. 
Leptin and cardiovascular risk S Söderberg et al
Leptin levels were not related to diabetes, hypertension, smoking status or treatment with diuretics, Ca 2 þ blockers and oral hypoglycaemic drugs but, as expected, were significantly higher in overweight and obese subjects ( Table 2) . Adiponectin levels were lower in current smokers but were not related to diabetes, hypertension, drug treatment or obesity. Leptin was correlated with BMI and triglyceride levels (Table 3) . Adiponectin increased with age, and with increasing NT-proBNP levels. Adiponectin was also positively correlated with plasma HDL cholesterol and negatively with plasma triglyceride concentration. Circulating levels of leptin and adiponectin were not correlated, and neither was correlated with the LIPID risk score. 16 The RR of a future recurrent cardiovascular event increased with increasing quartiles of leptin (P for trend ¼ 0.002), such that patients in the highest quartile had triple the risk of those in the lowest quartile (P ¼ 0.001) ( Table 4) . The relationship between high levels of leptin and the risk of a recurrent cardiovascular event persisted after adjustment for randomized treatment with pravastatin, treatment with diuretics, Ca 2 þ blockers and oral hypoglycaemic drugs, and for traditional risk factors according to the LIPID risk score and also after adjustment for obesity. However, the association was attenuated in the full model. The relationship between leptin and future recurrent cardiovascular events remained independently significant after adjustment for CRP and NT-proBNP. Adiponectin was not associated with recurrent cardiovascular events, either in the univariate or in the adjusted models.
Interactions between leptin and adiponectin, and between leptin and adiponectin on one hand and total cholesterol-to-HDL ratio, CRP and NT-proBNP on the other were tested (Table 5) . No interactions were found, and further adjustment for BMI categories did not add more information (data not shown).
The association between circulating levels of NT-proBNP with leptin and adiponectin was further tested by estimating age and BMI adjusted levels of leptin and adiponectin in subjects with NT-proBNP above and below the median. Adiponectin levels were higher in cases with high NTproBNP levels (10.0 (8.8-11.4) vs 6.7 (5.9-7.5)), whereas adiponectin did not differ in controls (8.0 (7.0-9.1) vs 7.2 (6.3-8.2)). Leptin did not differ between subjects with high or low NT-proBNP levels.
Discussion
High leptin levels significantly predicted further cardiovascular events in men with known CHD. This association Leptin and cardiovascular risk S Söderberg et al was independent of other risk factors tested separately, although not in the full model. The small sample size and the fact that both cases and controls had known atherosclerotic disease could explain this lack of strong association. As this was a nested case-control study in which the two groupsFcases and controlsFwere matched and selected post hoc on the basis of further cardiovascular events, our finding that the cases had higher plasma leptin concentrations must be interpreted cautiously. Nevertheless, the findings add to the growing body of evidence relating leptin to atherosclerotic cardiovascular disease. No association between adiponectin and cardiovascular events was found.
We and others have shown that leptin predicts further development of myocardial infarction in men, 8, 9 and in hypertensive men and women. 17 Leptin levels independently predict cardiovascular events in non-diabetic patients with angiographically confirmed coronary artery stenosis. 18 High levels characterized those who developed restenosis after coronary angioplasty. 19 Hyperleptinaemia predicts both haemorrhagic and ischaemic stroke, 20 and is more often present in patients with an acute stroke than control subjects. 21 Our study adds further evidence to the prognostic value of leptin levels, as high levels also predicted recurrent clinical cardiovascular events in a high-risk group with previous MI or unstable angina. It is thus possible that leptin specifically associates with processes in the plaque that leads to rupture and thrombosis formation as reviewed by Beltowski and Koh.
22,23
Leptin has multiple effects on metabolism, hormones and inflammatory and immune reactions. 1, 24 Human obesity is characterized by high leptin levels, 1 which probably reflects hypothalamic leptin resistance. Physiologically, leptin is probably an important regulator of metabolic and hormonal reactions during starvation. 25 Leptin may contribute to the development of classical risk factors for atherosclerosis such as arterial hypertension and diabetes mellitus. In particular, leptin may affect BP regulation by stimulation of the sympathetic system, effects on the renin-angiotensinogen-aldosterone system (RAAS) and by stimulation of natriuresis. 4 Leptin concentrations correlate directly with norepinephrin spillover rates and both are correspondingly reduced by weight reduction. 26 Related to this, we have shown independence between NT-proBNP and leptin. However, ANP and leptin are related, as ANP reduces leptin secretion, 27 and circulating levels of ANP are higher in leptintreated rats. 28 The association between natriuretic peptides and leptin is intriguing and needs further exploration. Leptin has important effects on inflammatory and immune reactions. 29 Leptin regulates T-cell proliferation and activation, and influences cytokine production towards a Th1 response. Leptin levels are correlated with circulating levels of CRP, 30 and exogenous leptin increases CRP levels in normal-weight subjects but not in obese subjects, 31 and CRP decreases markedly during fasting-induced hypoleptinaemia. 32 The known direct proatherogenic effects of CRP 33 may thus be partly regulated by leptin. Leptin interacts with lipid metabolism at several levels: by stimulating macrophages to secrete lipoprotein lipase in the vessel wall; 34 by increasing the accumulation of cholesterol esters in foam cells, especially during hyperglycaemia 6 and by lowering HDL through increased clearance consequent on the upregulation of the scavenger receptor. 35 In this study, we show that men treated with pravastatin have lower leptin levels. This is consistent with findings in rabbits given atorvastatin, 36 and the observation that polymorphisms in the leptin receptor are related to an attenuated response to simvastatin. 37 From these data, we suggest that one of many beneficial and pleotropic effects of statins may be lowering leptin levels. The higher levels of leptin in the case group reflect overweight-or obesity-induced adipokine secretion. There is considerable heterogeneity in this response, which may be modified by inflammation, exercise or diet. 38 This variable Abbreviations: NT-proBNP, brain natriuretic peptide; CRP, C-reactive protein; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol.
Leptin and cardiovascular risk S Söderberg et al adipokine response to obesity may partly explain the unclear relationship of BMI in CHD patients and the risk of recurrent events and the apparent 'obesity paradox' in some patient groups. 39 Adiponectin is produced exclusively by the adipocyte, and circulates in plasma mainly as high-order structures. 10 In contrast to leptin, adiponectin mRNA levels decrease with increasing obesity and women have higher levels, which cannot be explained by increased fat mass only. Omental fat tissue produces less adiponectin than subcutaneous fat, and circulating levels strongly correlates with measures of central obesity. Adiponectin levels are low in insulin-resistant subjects, and low levels predict the development of type 2 diabetes.
11
Over-expressing adiponectin protects against atherosclerosis in mice, possibly by the downregulation of vascular adhesion factors, inhibition of foam cell production and smooth muscle cell migration. 12 In humans, low levels relate to cardiovascular disease in cross-sectional studies, 40 and predict the development of myocardial infarction in men in the Physicians Health Study, 13 but not CHD in American
Indians. 14 Furthermore, did not predict the development of first ever stroke, 20 but was related to survival after ischaemic stroke. 41 Our current results should therefore be interpreted with caution, considering the size of the study. A further limiting factor might have been measuring the total adiponectin pool and not its subfractions. Myocardial dysfunction could affect circulating levels of adipokines, and adiponectin could possibly be harmful in this group, 42 thus abolishing the positive effects of high adiponectin levels. In this analysis, we used high levels of NT-proBNP as a proxy for myocardial dysfunction and we found that cases with high NT-proBNP had higher adiponectin levels (but not higher leptin levels). It is thus possible that the lack of association between adiponectin and the development of events was because of a dual effect of adiponectin. 43 In conclusion, plasma leptin predicted independently recurrent cardiovascular events (cardiovascular death, nonfatal myocardial infarction and stroke) in men with stable CHD. Leptin could be an important tool for risk prediction in the future. Furthermore, leptin may give new insights into the relation between obesity and increased risk for cardiovascular disease.
